Cigna & FTC Settle: Transforming Pharmacy Benefits Management
Cigna has announced a settlement with the Federal Trade Commission (FTC) concerning its pharmacy benefit manager, Express Scripts. This agreement represents a significant stride toward addressing regulatory compliance requirements. However, company executives assert that these changes will not impact Express Scripts' profitability.
Regulatory Reform and Business Model Transition
The FTC describes this settlement as a substantial reform of Express Scripts' business operations. Despite ongoing AI-driven prior authorization delays, many modifications were already in place as the PBM transitions to a rebate-free model. During a recent earnings call aligned with Cigna's fourth-quarter results, executives reassured investors of sustained profits, reporting an operational income increase of 16%.
Compensation Structure Modifications
The settlement mandates Express Scripts to shift from a drug savings-based model to a core administrative fee per member per prescription. With this change, the intent is to address industry concerns while maintaining profitability. Chief Operating Officer Brian Evanko emphasized the parity in expected profitability between the legacy and new models.
Implementation Timeline and Industry Impacts
Cigna plans to fully implement the new model by 2027, with significant adoption expected by 2028. Fortunately, the settlement does not levy financial penalties if employers choose not to transition. In tandem, regulations now demand increased transparency and the elimination of rebate-linked compensation in Medicare Part D, though executives remain optimistic about Express Scripts' earnings and client acquisition.
Strategic Response to Regulatory Pressures
Express Scripts' emphasis on scaling its rebate-free model is a strategic response to escalating regulatory pressures over PBM operations. Cigna CEO David Cordani outlined the transformative impact of market innovation, legislation, and regulation on the pharmacy services sector.
Financial Outlook and Growth Projections
Despite initial stock volatility post-FTC announcement, Cigna's stock recovered, supported by strong fourth-quarter earnings. Evernorth, encompassing Express Scripts, reported a 17% revenue increase. Although new model investments could slightly compress profit margins, Cigna anticipates considerable revenue growth, projecting $280 billion in 2026.
Throughout 2026, Cigna expects to maintain medical membership levels at 18.1 million, navigating industry challenges through strategic transformations. While investments and regulatory compliance requirements remain priorities, these strategic shifts aim to stabilize and enhance growth prospects.